Erratum: Skin thickness progression rate: A predictor of mortality and early internal organ involvement in diffuse scleroderma (Annals of the Rheumatic Diseases (2011) 70, (104-109) DOI:10.1136/ard.2009.127621);Skin thickness progression rate: A predictor of mortality and early internal organ involvement in diffuse scleroderma

Annals of the Rheumatic Diseases

Volumn 70, Issue 1, 2011, Pages 104-109

  Domsic, Robyn T ^a   Rodriguez Reyna, Tatiana ^b   Lucas, Mary ^a   Fertig, Noreen ^a   Medsger Jr , Thomas A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIFFUSE SCLERODERMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SKINFOLD THICKNESS; SURVIVAL; SYSTEMIC SCLEROSIS;

EID: 78650663333     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.127621corr1     Document Type: Erratum

References (28)

1. S teen V D, Medsger TA, Jr, Osial TA, Jr, e t al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76 : 779-86 .
2. Medsger TA, Jr, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21 ( 3 Suppl 29 ): S42 - 6 .
3. Perera A, Fertig N, Lucas M, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56 : 2740-6 .
4. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43 : 2445-54 .
5. Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56 : 2422-31 .
6. Steen VD, Medsger TA, Jr, Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43 : 2437-44 .
7. Altman RD, Medsger TA, Jr, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34 : 403-13 .
8. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classifi cation in the early stages of the disease. J. Rheum 1988; 15 : 276-83 .
9. Bennett R, Bluestone R, Holt PJ, et al. Survival in scleroderma. Ann Rheum Dis 1971; 30 : 581-8 .
10. B ryan C, Howard Y, Brennan P, et al. S urvival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 35 : 1122-6 .
11. Czirják L, Kumánovics G, Varjú C, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67 : 59-63 .
12. Eason RJ, Tan PL, Gow PJ. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med 1981; 11 : 657-62 .
13. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81 : 139-53 .
14. Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13 : 911-16 .
15. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57 : 682-6 .
16. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37 : 750-5 .
17. Jacobsen S, Ullman S, Shen G, et al. Infl uence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J. Rheum 2001; 28 : 11 .
18. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82 : 139-48 .
19. Medsger TA, Jr, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973; 26 : 647-60 .
20. Nagy Z, Czirják L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997; 16 : 454-60 .
21. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81 : 154-67 .
22. Simeón CP, Armadans L, Fonollosa V, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42 : 71-5
23. Valentini G, Medsger TA, Jr, Silman AJ, et al. Conclusion: and identifi cation of the core set of variables to be used in clinical investigations. Clin Exp Rheumatol 2003; 21 ( 3 Suppl 29 ): S47 - 8 .
24. Vlachoyiannopoulos PG, Dafni UG, Pakas I, et al. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000; 59 : 359-67 .
25. W ynn J, Fineberg N, Matzer L, e t al. P rediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110 : 123-7
26. Farmer RG, Gifford RW, Jr, Hines EA, Jr, Prognostic signifi cance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases. Circulation 1960; 21 : 1088-95 .
27. White B, Bauer EA, Goldsmith LA, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995; 38 : 351-60.
28. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010. Published Online First: 15 June 2010. doi: 10.1136/ ard.2009.114264.